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Silencing Autocrine Death: A Ubiquitin
Ligase that Blocks Activation-Induced
Cell Death in Cutaneous T-Cell
Lymphoma
Claus-Detlev Klemke1, Maria Feoktistova2 and Martin Leverkus1,2
Cutaneous T-cell lymphoma (CTCL) tumor cells lack the ability of activated T cells
to undergo TCR/CD3-mediated activation-induced cell death (AICD). In this issue,
the study reported by Wu et al. demonstrates that c-CBL (Casitas B-lineage
Lymphoma proto-oncogene) is overexpressed in CTCL. When CTCL cells lose
c-CBL, AICD is enhanced. Furthermore, combination therapy with methotrexate
(a known demethylating agent for the CD95 gene) in combination with the loss of
c-CBL increases CTCL cell death. Therefore, inhibition of c-CBL could represent a
method of sensitizing lymphoma cells to enhance AICD. Armed with their novel
data, the investigators envision combination therapies that target c-CBL to
reactivate AICD in the malignant T cells whenever responsiveness to TCR/CD3
signaling is retained.
Journal of Investigative Dermatology (2015) 135, 662–665. doi:10.1038/jid.2014.468
Cutaneous T-cell lymphomas (CTCLs)
are a heterogeneous group of extranodal
non-Hodgkin lymphomas with an esti-
mated annual incidence of 1/100,000.
Mycosis fungoides (MF) and the Se´zary
syndrome (SS), characteristically the
most frequent forms of CTCL, are most
commonly treated by dermatooncolo-
gists (Klemke, 2014). One important
hallmark of cancer that is thought to
represent an obstacle to therapy of
CTCL is cell death resistance (Hanahan
and Weinberg, 2011). Most types of
CTCL run an indolent course over
years to decades, with skin lesions that
persist (patches and plaques). This
clinical observation suggests a
pathophysiological relevant defect in
apoptosis rather than increased
proliferation as important in disease
development. It has been known for a
long time that one characteristic of
CTCL cells relevant for tumor progres-
sion and overall prognosis is the deve-
lopment of resistance to CTCL cell–
intrinsic apoptosis. A signaling pathway
that holds promise to break acquired
cell death resistance in CTCL is the
death receptor (DR)-induced cell death
pathway, which is controlled, at least in
part, by CD95/CD95 ligand (CD95L), a
process coined as activation-induced
cell death (Krammer et al., 2007).
CD95-induced cell death is the proto-
typical example of extrinsic cell death,
which can also be induced by other
membrane-bound and soluble ligands
(death ligands; DL), such as tumor
necrosis factor–related apoptosis-indu-
cing ligand and tumor necrosis factor.
Stimulation of the DR results in initia-
tion of an intracellular signaling cas-
cade, and a critical step during this
process is the activation of pro-cas-
pase-8 within the death-inducing signal-
ing complex (DISC). The initiator,
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caspase-8, forms stimulation-dependent
chains within the DISC (Dickens et al.,
2012; Schleich et al., 2012), is then
cleaved in a DISC-associated manner
by autoproteolysis, and enhances cell
death by the activation of effector
caspases such as caspase-3. When
direct activation of effector caspases is
insufficient, DR–initiated signals can be
augmented via the mitochondrial (intrin-
sic) pathway. The cross talk between
extrinsic and intrinsic cell death path-
ways is governed by Bcl-2 proteins, in
particular by another caspase-8 sub-
strate, the BH3-protein Bid. Cleaved
Bid (truncated Bid (tBid)) interacts
directly and activates multidomain pro-
apoptotic Bcl-2 proteins (e.g., Bax or
Bak). Each step of this cell death signal-
ing cascade is tightly controlled by anti-
apoptotic proteins to ensure that under
physiological conditions deleterious cell
death is avoided. The cellular FLICE-like
inhibitory protein (cFLIP), a DISC-asso-
ciated protein, is responsible for sup-
pressing extrinsic cell death. cFLIP
inhibits caspase-8 cleavage/activation
and, therefore, release from the DISC;
it thereby suppresses DL-induced apop-
tosis (for review see Lavrik and Krammer
(2012)).
CTCL: a diseased T cell that lacks the
ability to undergo AICD
For CTCL, most importantly SS, it has
been demonstrated convincingly that
TCR signaling of tumor cells is defective.
TCR activation first results in activation
of T-cell proliferation and—in a timed
manner to assure elimination of acti-
vated T cells—the induction of cell
death via CD95/CD95L interaction. Cell
death resistance of CTCL cells has been
explained, at least in subsets of CTCL
patients or cell lines, to a faulty activa-
tion-induced cell death (AICD), which is
physiologically induced in T cells upon
prolonged activation (for review see
Krammer et al. (2007)). Defective AICD
in CTCL can result from tumor cell–
intrinsic expression of cFLIP (Contassot
et al., 2008) or by flawed upregulation
of the CD95L that is critical for the
execution of cell death (Klemke et al.,
2009). In addition, CTCL cells were
shown to have a blockade of CD95L
mRNA transcription by loss of the
general transcriptional regulator special
AT-rich region binding protein 1 (Wang
et al., 2011) or by transcriptional
repression of CD95 (Wu et al., 2009).
Moreover there are other intracellular
mechanisms and signals usually
activated by the TCR that are flawed in
CTCL cells. These include defective
phosphorylation of PLCg1, a lack of
calcium influx, and the absence of
reactive oxygen intermediates (reactive
oxygen species (ROS)) production in
CTLC cells upon CD3/TCR stimulation
(Klemke et al., 2009). Intriguingly, the
gene encoding PLCg1 was recently
shown to carry activating mutations in
advanced stages of CTCL (tumor stage
MF and SS patient samples), hinting at
the possibility that increased prolifera-
tion of tumor cells is a relatively late
event during tumor progression of CTCL
(Vaque et al., 2014). Rather cell death
resistance could be considered a CTCL
defect and thought to represent an
earlier event during tumorigenesis. The
lack of some of the numerous TCR-
generated signals pointed out above
prevents induction of the CD95L, and
thereby protects CTCL cells from AICD,
and this hints to the possibility that
deviation of TCR signaling is a pre-
requisite for the defective AICD that is
found in Se´zary cells. Beyond inhibition
of AICD, more recent findings point to a
role for KIR3DL2 signaling as additional
promising candidate to induce caspase-
mediated cell death in CTCL cells,
because Se´zary cells express this natural
killer cell receptor (Ghazi et al., 2014).
Taken together, over the past 5 years, the
accumulation of Se´zary cells is explained
by increased cell death resistance, in
particular by cell-intrinsic strategies that
obstruct signaling pathways necessary to
eliminate T cells upon TCR activation
(Figure 1). Further understanding and
ultimately targeting defective TCR signal-
ing and/or overcoming the lack of TCR-
induced CD95L holds promise as a
therapeutic strategy for CTCL.
c-CBL is an ubiquitin ligase overexpressed
in CTCL: potential novel therapeutic
target?
Wu et al. (2014) shed new light on this
facet of CTCL pathogenesis. Their group
explored a molecule relevant to intra-
cellular signaling by the TCR, and
they studied c-CBL (Casitas B-lineage
Lymphoma proto-oncogene). As shown
in the paper, c-CBL is expressed at
higher levels in CTCL. Knockdown of
c-CBL restored the distorted AICD path-
way CTCL tumor cells in response to
PLC-g1 phosphorylation (with subseq-
uent Ca2þ release and ROS generation).
These two intracellular signals are both
required for the induction of CD95L
expression, which leads to autocrine
and paracrine tumor cell death (AICD).
C-CBL has been associated with a
plethora of functions in mammals, but
it acts mainly as an adaptor protein with
RING-type E3 ubiquitin ligase activity,
leading to the degradative ubiquitina-
tion of cytokine receptors. Of interest, it
has also been associated with ubiquiti-
nation of the TCR/CD3 complex (Dikic
and Schmidt, 2007). Although not dire-
ctly confirmed as a c-CBL substrate, it
seems plausible that (mono)-ubiquiti-
nation of the TCR/CD3 complex by
c-CBL could result in modulation of
TCR function. Examples of this would
include internalization and subsequent
Clinical Implications
 Se´zary syndrome (SS) cells lack the ability of activated T cells to undergo
TCR/CD3-mediated activation-induced cell death (AICD).
 The study by Wu et al. in this issue reveals that c-CBL (Casitas B-lineage
Lymphoma proto-oncogene) is overexpressed in SS/MF, and loss of c-CBL
results in sensitization to AICD.
 The combination of methotrexate, known to demethylate the CD95 gene,
with loss of c-CBL, enables rapid induction of cell death in CTCL cells. The
investigators envision combination therapies that target c-CBL to reacti-
vate AICD in malignant T cells that retain the ability to respond to TCR/CD3
signals.
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lysosomal degradation or, alternatively,
intracellular repression or deviation of
TCR/CD3 signaling necessary for CD95L
induction and subsequent AICD. It is
also possible that c-CBL activity may
counteract TCR cell surface expression,
thereby repressing TCR signaling,
although this hypothesis awaits experi-
mental examination (Figure 1). The
authors also explored the impact of
methotrexate (MTX), a drug commonly
used to treat CTCL. In their previous
studies, they reported that MTX acts, at
least in part, by demethylation of the
CD95 promoter that is hypermethylated
in a number of CTCL cell lines. MTX
treatment of CTCL tumor cells increased
CD95 surface expression, which is
essential for AICD via tumor cell-
intrinsic induction of CD95L (e.g., via
knockdown of c-CBL). When they com-
bined knockdown of c-CBL with MTX, a
highly synergetic cell death of tumor
cells was achieved, indicating that the
tumor promoting effect of c-CBL and
methylation of the CD95 promotor
protected CTCL cells from AICD. This
suggested combining MTX with other
treatment modalities that enable AICD
of CTCL tumor cells.
Reactivation of AICD (or inhibition of
c-CBL) as a therapeutic principle in
intermediate stages of CTCL
A number of important questions arise
from the results of the study by Wu et al.
(2014). First, what is the functional state
of c-CBL in patients with SS/MF? Wu
et al. explored this question using loss-
of-function studies with transient knock-
down of c-CBL. Under those conditions,
they found increased CD95L expression
and subsequent SS/MF cell death. These
data suggest that in CTCL most likely
c-CBL is not expressed in a nonfunc-
tional state but rather acts via active
modulation of TCR/CD3 signaling. It
will nonetheless be important to deter-
mine whether the c-CBL gene carries
mutations in CTCL. Previous evidence
suggests that the impact of mutations in
c-CBL appear to have roles in other
diseases: Patients with myeloid neo-
plasms carry gain-of-function mutations
of c-CBL (Sanada et al., 2009), whereas
loss-of-function mutations of c-CBL
were associated with a predisposition
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Figure 1. Cell death signaling in cutaneous T-cell lymphoma (CTCL). The impact of Casitas B-lineage Lymphoma proto-oncogene (c-CBL) on resistance to T-cell
death and autocrine death signaling in cutaneous lymphoma. In T cells, elimination of activated T cells is achieved via TCR/CD3-mediated signals that, via PLCg1,
reactive oxygen species (ROS), and Caþ signaling, induce CD95/CD95 ligand (CD95L). CD95L then induces cell death via death-inducing signaling complex
recruitment and activation of caspase-8 and consequent effector caspase activation. PLCg1 also activates proliferative signaling via the transcription factor NF-AT.
Early tumor cells of Se´zary syndrome (SS) are inhibited by c-CBL via not yet fully understood mechanisms, likely ubiquitination of TCR/CD3 components and
subsequent deviation of TCR signaling. These TCR-induced signals are unable to activate PLCg1 or ensuing intracellular signals that include transcription of
CD95L. The cell death cascade in SS cells is blocked at multiple levels (red marked), including loss of CD95, upregulation of cellular FLICE-like inhibitory protein
(cFLIP), or interference with CD95L transcription by special AT-rich region binding protein 1 (SATB1). KIR3DL2 signaling by CpG oligodeoxynucleotide (ODN) is
able to influence TCR signaling and caspase activation in CTCL tumor cells. In late-stage disease, activating PLCg1 mutations deviate signaling in SS cells to
hyperproliferation via nuclear factor of activated T cells (NF-AT)-induced transcription.
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to juvenile myelomonocytic leukemia
(Niemeyer et al., 2010). Obviously, it
will be useful to study chromosomal
aberrations, point mutations, and/or
translocations in c-CBL in SS/MF by
examining the respective genomic
locus at 11q23.3. Although microarray-
based gene expression studies of CTCL
tumor cell samples did not show
significant alterations in c-CBL gene
expression (Booken et al., 2008), it is
tempting to speculate that c-CBL regu-
lation may occur at the post-trans-
criptional level. In general, c-CBL has
been implicated in the downregulation
of cytokine responses. In essence, the
absence of c-CBL favors a cytokine
response, as, for example, T cells
lacking c-CBL show a hyperrespon-
siveness to IL-7 (Rathinam and Flavell,
2010). In this context it is also important
to understand the role(s) of c-CBL during
CD3/TCR internalization. It could be
hypothesized that c-CBL promotes TCR
internalization, a well-known pheno-
menon that downregulates TCR surface
expression (Wang et al., 2010). Thus,
overexpression of c-CBL may interfere
with TCR expression, representing an
additional molecule that is able to
inhibit TCR-induced CD95L expres-
sion. If this is the case, then interfering
with c-CBL may represent a treatment
option for SS/CTCL. Alternatively, as
c-CBL mutations are known to activate
the RAS pathway, it would be interest-
ing to explore RAS-interfering drugs
(e.g., MAPK/ERK kinase inhibitors) in
CTCL. Either way, awakening autocrine
T-cell death remains a strategy worth
examination for CTCL therapy.
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